Background Depressive symptoms are often seen in schizophrenia. The overlap in presentation makes it difficult to distinguish depressive symptoms from the negative symptoms of schizophrenia. The adipokine leptin was found to be altered in both depression and schizophrenia. There are few studies focusing on the prediction of leptin in diagnosis and evaluation of depressive symptoms in schizophrenia.
ObjectiveAims To assess the plasma leptin level in patients with schizophrenia and its relationships with depressive symptoms.
Methods Cross-sectional studies were applied to (1) compare the levels of plasma leptin between schizophrenia (n=74) and healthy controls (n=50); and (2) investigate the relationship between plasma leptin levels and depressive subscores.
Results (1) Plasma leptin levels were significantly higher in patients with schizophrenia than in healthy controls. (2) Correlation analysis revealed a significant negative association between leptin levels and the depressed factor scores on the Positive and Negative Syndrome Scale (PANSS). (3) Stepwise multiple regression analyses identified leptin as an influencing factor for depressed factor score on PANSS.
Conclusion Leptin may serve as a predictor for the depressive symptoms of chronic schizophrenia.
- depressive symptoms
- chronic schizophrenia
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0
Statistics from Altmetric.com
JX and YJ contributed equally.
Authors’ contributions DC and DQ were responsible for study design and revising. JX, MX, YL, YS and WD were responsible for clinical data collection and lab experiments. JX, YJ and DQ managed the literature search and the statistical analyses. JX drafted the manuscript. DC, DQ, YP and CZ participated in revising the manuscript. All authors read and approved the final manuscript.
Funding This study was supported by grants from the National Key R&D Program of China (2017YFC0909200), the National Science Foundation of China (NSFC; 81171266, 81271481, 81671336 and 81500976), the China and National Key Research and Development Program (2017YFC0909200), the Shanghai Key Laboratory of Psychotic Disorders (13dz2260500), the Shanghai Municipal Planning Commission of Science and Research Fund (20154Y0194) and the Canadian Institutes of Health Research (project grant PJT-156116).
Competing interests None declared.
Informed consent Obtained.
Ethics approval Institutional Review Board of Shanghai Mental Health Center.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.